Evolus, Inc. reported its financial results for the third quarter of 2025, revealing a total net revenue of $68.97 million, a 12.9% increase from $61.09 million in the same period last year. The growth was primarily driven by the launch of its Evolysse™ product line, which contributed $5.73 million in product revenue. The company’s product revenue for the quarter was $68.97 million, compared to $60.16 million in the prior year, while service revenue decreased to zero from $0.92 million. Despite the revenue increase, Evolus recorded a net loss of $15.74 million, an improvement from the $19.17 million loss reported in Q3 2024.
In the nine months ending September 30, 2025, Evolus generated total net revenues of $206.88 million, up from $187.33 million in the same period of 2024, marking a 10.4% increase. The company’s cost of goods sold also rose, totaling $69.06 million for the nine-month period, compared to $57.66 million in the previous year. This increase in costs was attributed to higher sales volumes of both Jeuveau® and Evolysse™ products. The gross profit margin for the nine months was 66.6%, down from 69.2% in 2024, reflecting the impact of increased costs associated with product launches and sales.
Evolus has made significant strategic moves, including the launch of Evolysse™ Form and Evolysse™ Smooth in April 2025, with plans to introduce additional Evolysse™ products in Europe by mid-2026. The company also entered into an Amended and Restated Loan Agreement with Pharmakon, securing a senior secured term loan of up to $250 million, which will support its ongoing operations and product development. As of September 30, 2025, Evolus had cash and cash equivalents of $43.52 million, down from $86.95 million at the end of 2024, and an accumulated deficit of $661.17 million.
Operationally, Evolus has focused on expanding its customer base and increasing product adoption in a competitive market. The company reported a restructuring initiative that incurred costs of $1.44 million, aimed at optimizing its cost structure. The total employee headcount and customer engagement metrics were not disclosed in the filing, but the company emphasized its commitment to enhancing its marketing strategies and sales force to drive future growth.
Looking ahead, Evolus anticipates continued revenue growth driven by the success of its Evolysse™ products and the regulatory approval of additional product candidates. However, the company remains cautious about potential economic challenges, including inflation and consumer spending trends, which could impact its financial performance. Evolus plans to leverage its existing capital resources and may seek additional financing to support its long-term growth objectives.
About Evolus, Inc.
Evolus, Inc. is a global aesthetic company specializing in non-reimbursed, consumer-pay medical products. Its core offerings include injectable neurotoxins like Jeuveau and hyaluronic acid gels such as Evolysse. Serving aesthetic practitioners and consumers worldwide, the company emphasizes high-quality, minimally invasive treatments, digital marketing, and strategic licensing to drive growth in the expanding medical aesthetics market.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.